BMY — Bristol-Myers Squibb Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual income statement for Bristol-Myers Squibb Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	26,145	42,518	46,385	46,159	45,006
Cost of Revenue
Gross Profit	18,341	31,385	36,784	36,085	34,404
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	19,758	49,365	37,770	36,494	35,583
Operating Profit	6,387	-6,847	8,615	9,665	9,423
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	4,975	-6,871	8,098	7,713	8,440
Provision for Income Taxes
Net Income After Taxes	3,460	-8,995	7,014	6,345	8,040
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	3,439	-9,015	6,994	6,327	8,025
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,439	-9,015	6,994	6,327	8,025
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.58	-0.2	3.81	3.13	3.75
Dividends per Share